Targeted therapy of BRAF V600E‐mutant histiocytic sarcoma: A case report and review of the literature
- 23 August 2019
- journal article
- review article
- Published by Wiley in European Journal of Haematology
- Vol. 103 (4) , 444-448
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineagesBlood, 2016
- Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell DisordersAmerican Journal of Surgical Pathology, 2016
- Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signalingLeukemia, 2015
- Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1Oncotarget, 2015
- Successful Treatment of Multifocal Histiocytic Sarcoma Occurring after Renal Transplantation with Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) Followed by Allogeneic Hematopoietic Stem Cell TransplantationCase Reports in Hematology, 2015
- BRAFV600E Mutation in a Histiocytic Sarcoma Arising From Hairy Cell LeukemiaJournal of Clinical Oncology, 2014
- Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenibNeurology, 2014
- Frequent detection of BRAFV600E mutations in histiocytic and dendritic cell neoplasmsHistopathology, 2014
- Human leukocyte antigen-haploidentical hematopoietic stem cell transplant for a patient with histiocytic sarcomaLeukemia & Lymphoma, 2012
- Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplantAmerican Journal of Hematology, 2007